Outlook To Make Its Case For Ophthalmic Bevacizumab At High-Stakes EMA Meeting

Developments are heating up on the regulatory front with regard to Outlook Therapeutics’ bid to become the first company to secure EU marketing approval for an ophthalmic formulation of bevacizumab.

Outlook’s investigational product, brand name Lytenava (ONS-5010), for wet age-related macular degeneration (wet AMD), is listed as being up for a possible oral explanation meeting with the European Medicines Agency’s human medicines committee, the CHMP, on 20 February, according to the draft agenda of the latest CHMP monthly meeting taking place on 19-22 February